42 results about "Primary amino acids" patented technology

Methods, compositions, kits, and apparatus are provided wherein the aminoacyl-tRNA synthetase system is used to analyze amino acids. The method allows very small devices for quantitative or semi-quantitative analysis of the amino acids in samples or in sequential or complete proteolytic digestions. The methods can be readily applied to the detection and / or quantitation of one or more primary amino acids by using cognate aminoacyl-tRNA synthetase and cognate tRNA. The basis of the method is that each of the 20 synthetases and / or a tRNA specific for a different amino acid is separated spatially or differentially labeled. The reactions catalyzed by all 20 synthetases may be monitored simultaneously, or nearly simultaneously, or in parallel. Each separately positioned synthetase or tRNA will signal its cognate amino acid. The synthetase reactions can be monitored using continuous spectroscopic assays. Alternatively, since elongation factor Tu:GTP (EF-Tu:GTP) specifically binds all AA-tRNAs, the aminoacylation reactions catalyzed by the synthetases can be monitored using ligand assays. Microarrays and microsensors for amino acid analysis are provided. Additionally, amino acid analysis devices are integrated with protease digestions to produce miniaturized enzymatic sequenators capable of generating either N- or C-terminal sequence and composition data for a protein or peptide. The possibility of parallel processing of many samples in an automated manner is discussed.

Methods, compositions, kits, and apparatus are provided wherein the aminoacyl-tRNA synthetase system is used to analyze amino acids. The method allows very small devices for quantitative or semi-quantitative analysis of the amino acids in samples or in sequential or complete proteolytic digestions. The methods can be readily applied to the detection and / or quantitation of one or more primary amino acids by using cognate aminoacyl-tRNA synthetase and cognate tRNA. The basis of the method is that each of the 20 synthetases and / or a tRNA specific for a different amino acid is separated spatially or differentially labeled. The reactions catalyzed by all 20 synthetases may be monitored simultaneously, or nearly simultaneously, or in parallel. Each separately positioned synthetase or tRNA will signal its cognate amino acid. The synthetase reactions can be monitored using continuous spectroscopic assays. Alternatively, since elongation factor Tu:GTP (EF-Tu:GTP) specifically binds all AA−tRNAs, the aminoacylation reactions catalyzed by the synthetases can be monitored using ligand assays. Microarrays and microsensors for amino acid analysis are provided. Additionally, amino acid analysis devices are integrated with protease digestions to produce miniaturized enzymatic sequenators capable of generating either N- or C-terminal sequence and composition data for a protein or peptide. The possibility of parallel processing of many samples in an automated manner is discussed.

The invention relates to a method for preparing bonito stick protein hydrolysate with an effect of reducing uric acid. The method comprises the following main steps of raw material heat treatment, restriction digestion, membrane separation-anion exchange chromatography-gel filtration chromatography separation, concentration and spray drying so as to obtain the bonito stick protein hydrolysate with an effect of reducing uric acid. The amino acid analysis indicates that the zymolyte peptide fragment primary amino acid sequence contains four amino acids, namely histidine, arginine, lysine and threonine, the total mass content of the four amino acids is 70 percent of the total amino acid content of zymolyte. MALDI-TOF-MS mass spectrum determines that the molecular weight of the main peptide effective ingredient is less than 700Da. In-vitro uric acid reduction experiments prove that the bonito stick protein hydrolysate has a remarkable effect of inhibiting generation of uric acid, and has an inhibition rate over 50 percent; an oteracil potassium molded hyperuricemic rat animal model indicates that the bonito stick protein hydrolysate can be used for remarkably reducing the level of serum uric acid and serum creatinine of rats, and shows a relatively good kidney protecting effect.

Pyridinium-Betain compounds of the general formula (A):wherein R1 is H or a primary amino acids that is attached to the structure,X is OH or its ionized form O−,Y is OH, SH, or their ionized forms O− and S−,Z is H, an alkyl group, or a glycosidic group, or a phosphate or ester derivative thereof, andn is an integer of 0 to 4 to represent the chain length of the compound.A counter-ion is associated with these compounds and is preferably an ion of sodium, potassium, ammonium, calcium, magnesium, chloride, nitrate, carbonate, sulphate, phosphate, or the like. These compounds can be used as taste modifiers in various foodstuffs.

This invention relates to substantially purified gelonin, toxic fragments thereof, the DNA sequences encoding gelonin and use of the DNA for producing, by recombinant technology, gelonin, toxic fragments thereof and fusion proteins. More specifically, the invention relates to the primary amino acid sequence of gelonin, and of the DNA encoding said gelonin and the production of synthetic gelonin and toxic fragments thereof.

Disclosed is a thermoplastic melt-mixed composition including: a) a polyamide resin; b) 0.50 to about 5.0 weight percent of one or more amino acid selected from the group consisting of primary amino acids and secondary amino adds; said amino add having no hydroxyl groups and no more than one carboxylic add; optionally, c) one or more polyepoxy compound including at least two or more epoxy groups; d) reinforcing agent; e) polymeric toughener; and f) further additives; wherein the weight percents of components a), b), c) d) e) and f) are based on the total weight of the thermoplastic melt-mixed composition. Also disclosed are processes for making the compositions.

The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.

Variants of hedgehog protein that contain N-terminal modifications are described that can block hedgehog function; thus allowing these variants to serve as functional antagonists. These peptides have a primary amino acid sequence lacking the ability to elicit a hedgehog-dependent response in C3H 10T1 / 2 cells but having the ability to bind to the hedgehog receptor, patched-1. Methods for producing such functional antagonists and methods of using the functional antagonists are also described.

The invention provides a protein composition derived from silk fibroin, which composition possesses enhanced solubility and stability in aqueous solutions. The primary amino acid sequence of native fibroin is modified in the SDP such that cysteine disulfide bonds between the fibroin heavy and fibroin light protein chains are reduced or eliminated. Additionally, the composition can have a serine content that is reduced by greater than 40% compared to native fibroin protein, and the average molecular weight of the SDP is less than about 100 kDa.

The invention provides an anti-tumor fusion protein, which has the following primary amino acid sequence structure: EGFR-specific targeting oligopeptide-connecting peptide-lidamycin apoprotein-connecting peptide-TRAIL functional peptide fragment, wherein the EGFR-specific targeting oligopeptide has an amino acid sequence shown in a SEQ ID NO: 1, the lidamycin apoprotein has an amino acid sequence shown in an SEQ ID NO: 2, and the TRAIL functional peptide fragment has an amino acid sequence shown in an SEQ ID NO: 3. The fusion protein is an EGFR and DR4 / DR5 targeted bispecific fusion protein, and contains an EGFR targeted ligand oligopeptide, and the sensitivity of tumor cells to TRAIL and the natural drug resistance of reverse tumor cells to TRAIL are enhanced by an antagonistic EGFR signaling pathway. The invention also provides a coding gene of the fusion protein, an intensive fusion protein assembled with a lidamycin chromophore, and a pharmaceutical application of the intensive fusion protein.

The present invention provides a method utilizing primary amino acid sequence of a protein, energy minimization, molecular dynamics and protein vibrational modes to predict three-dimensional structure of a protein. The present invention also determines possible intermediates in the protein folding pathway. The present invention has important applications to the design of novel drugs as well as protein engineering. The present invention predicts the three-dimensional structure of a protein independent of size of the protein, overcoming a significant limitation in the prior art.

The invention provides a method for detecting doping of other collagen-containing substances in edible bird's nest. The method comprises the following steps: 1) pre-treatment of a sample of edible bird's nest: dividing the sample of the edible bird's nest into two parts, wherein one part employs acid for hydrolysis treatment and fixes the volume to be taken as an acid hydrolysis sample, the other part employs basic for hydrolysis treatment and fixes the volume to be taken as a basic hydrolysis sample, mixing the acid hydrolysis sample and the basic hydrolysis sample, fixing the volume, and taking a mixture as the pre-treatment sample; 2) pre-column derivatization treatment: respectively performing pre-column derivatization on primary amino acid and secondary amino acid of the pre-treated sample by OPA and FMOC to obtain a to-be-measured sample; and 3) respectively performing high performance liquid chromatography detection and analysis on the to-be-measured sample and a standard sample, by comparing the detection spectrums, determining whether the to-be-measured sample contains hydroxyproline and / or sarcosine or not, and whether the standard sample contains the standard object of hydroxyproline and / or sarcosine or not. The method is helpful for determination of quality of the edible bird's nest, and has the advantages of rapid analysis process and sensitive detection.

The invention discloses a fresh animal medicinal composition and a method for measuring the content of Chinese medicines of the fresh animal medicinal composition. The method comprises the following steps of: putting the fresh animal medicinal composition and the Chinese medicines into a measuring flask, dissolving by adding water, performing ultrasonic extraction and centrifugation, taking supernate, and sieving the supernate with a microporous filtering film to obtain a free amino acid test sample solution; and weighing the fresh animal medicinal composition and the Chinese medicines, fullydissolving by adding water, then performing ultrasonic extraction and centrifugation, taking the supernate, putting the supernate into an ampoule bottle, adding hydrochloric acid, performing vacuum nitrogenization and hydrolyzation, taking the mixture out, cooling the mixture to room temperature, adding a NaOH solution, uniformly mixing, transferring to the measuring flask, diluting by adding water, and fixing the volume to a scale, uniformly mixing, centrifuging, taking the supernate, and sieving the supernate with the microporous filtering film to obtain the total amino acid test sample solution. A chromatographic column is used for detecting primary amino acid and secondary amino acid. A mobile phase A comprising acetonitrile, methanol and water and a mobile phase B comprising Na2HPO4 of which the pH is 7.8 are used for performing gradient elution. The method is simple in operation and high in measurement resolution and sensitivity, and by the method, 12 to 26 types of amino acids in the fresh animal medicinal composition and the Chinese medicines thereof can be separated in a short time, so the method is a reliable method for measuring the amino acid content.

The invention provides a gene of an encoded antibacterial peptide, a gene of fusion protein and a recombinant vector and belongs to the field of pharmaceutics. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 1. The fusion protein has the following primary amino acid sequence structure: vector protein-connecting peptide-antibacterial peptide, wherein the antibacterial peptide has the amino acid sequence shown as SEQ ID NO: 1. The antibacterial peptide provided by the invention has helicobacter pylori resisting activity and has relatively strong stability and antibacterial activity in a stomach environment; a cell membrane is perforated through a physical effect and the effect of resisting helicobacter pylori is realized; the helicobacter pylori does not easily have drug resistance in a utilization process of the antibacterial peptide.

The invention provides an antibacterial peptide with helicobacter pylori resisting activity and fusion protein containing antibacterial peptide and belongs to the field of pharmaceutics. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO: 1. The fusion protein has the following primary amino acid sequence structure: vector protein-connecting peptide-antibacterial peptide, wherein the antibacterial peptide has the amino acid sequence shown as SEQ ID NO: 1. The antibacterial peptide provided by the invention has the helicobacter pylori resisting activity and has relatively strong stability and antibacterial activity in a stomach environment; a cell membrane is perforated through a physical effect and the effect of resisting helicobacter pylori is realized; the helicobacter pylori does not easily have drug resistance in a utilization process of the antibacterial peptide.

This invention pertains to nucleic acid fragments encoding plant glucosyltransferases, heretofore undescribed, that exhibit catalytic activity with p-hydroxybenzoic acid (pHBA) as a substrate and only attach glucose to the aromatic carboxyl group of pHBA, to form the pHBA glucose ester. These enzymes have potential applications both in vitro and in vivo, and their primary amino acid sequences can be used to identify other proteins that have similar kinetic properties.

Disclosed is a thermoplastic melt-mixed composition including: a) a polyamide resin; b) a poly(amino acid)-polyol compound provided by reacting: b1) one or more amino acids selected from the group consisting of primary amino acids and secondary amino acids and combinations of these; the amino acid having no more than one hydroxyl group; and b2) one or more polyepoxy compound comprising at least two or more epoxy groups; the poly(amino acid)-polyol compound having a range of at least 10 percent conversion of epoxy equivalents of component (b1) up to, but excluding, the gel point of the components b1) and b2) and c) reinforcing agent; and, optionally, d) polymeric toughener; and f) further additives. Processes for making the composition are also disclosed.

The invention discloses a flavor-enhancing umami tripeptide and derivatives and application thereof. A primary amino acid sequence of the tripeptide is Ser-Phe-Glu; a first derivative structural formula of the tripeptide is shown as a formula I, a second derivative chemical formula is shown as a formula II, and the derivatives are thermal reaction products of the tripeptide; third and fourth derivatives of the tripeptide are maillard reaction products namely glycopeptide compounds in structural formulas shown as a formula III and a formula IV. The tripeptide with flavor-enhancing and umami characteristics generates the derivatives with strong flavor-enhancing characteristics under heating or maillard reaction, and adding the derivatives into quick-freeze foods, soy sauce, vinegar, beverages and broth or seasonings can effectively improve umami, mellowness and durability.

A solvent for selective absorption of CO2 from the flue gas from a combustion plant is provided. The solvent includes an aqueous solution of a secondary amino acid salt as an active scrubbing substance and an additive, the additive including a primary amino acid salt. A process for providing an absorption liquid is also provided as well as a process for activating a solvent.

The invention provides a method for preparing a liquid organic fertilizer by enzymolysis and fermentation of pigskin, which comprises the following steps: (1) rinsing raw pigskin with clear water until the pH value of the used cleaning water is 6.5-8.0, and cutting the cleaned raw pigskin into pigskin fragments; (2) adding the pigskin fragments into a stirring tank, adding water with the same volume as the pigskin fragments, adding protease, heating to 35-60 DEG C, stirring for enzymolysis, and supplementing the pigskin fragments with the same mass for continuous enzymolysis after complete dissolution, with supplementation being performed for four times in total to obtain polypeptide enzymatic hydrolysate; (3) heating the polypeptide enzymatic hydrolysate to 70-90 DEG C to inactivate the protease, then cooling to 30-50 DEG C, adding aminopeptidase, and stirring for enzymolysis to obtain a primary amino acid liquid fertilizer; (4) adding a microbial agent into the primary amino acid liquid fertilizer obtained in the step (3) for fermentation and deodorization to obtain fermentation liquor; and (5) adding boric acid and zinc sulfate into the obtained fermentation liquor, dissolving,sub-packaging, sealing and storing. The prepared liquid organic fertilizer is high in amino acid content, free of concentration treatment and good in fertilizer efficiency.

The invention discloses a purifying device of an amino acid. The purifying device comprises a primary purifying section, a pre-purifying section, a post-purifying section and a collecting section, wherein an amino acid mother liquid is firstly subjected to separation and purification through the primary purifying section, and is subjected to online monitoring through a primary liquid chromatograph; high-concentration amino acid liquid of which the amino acid mass fraction is higher than 99.0% is directly introduced into the collecting section to collect; the residual primary amino acid liquid is introduced into the pre-purifying section to be purified again; the effluent primary inorganic salt is introduced into the post-purifying section to be purified again, the mixed amino acid is separated out, and finally the separated liquid is collected. According to the purifying device, the amino acid mother liquid can be separated and purified; the concentration of the amino acid in the purified amino acid liquid is higher than 99.0%; and the amino acid is thoroughly separated from the inorganic salt.

An exemplary embodiment may be directed to a fluorescence polarization assay that screens compounds or agents for their affinity to hematopoietic prostaglandin D synthase (H-PGDS) based on their ability to displace a fluorophore-containing detection analyte bound to an enzyme comprising the primary amino acid sequence of H-PGDS. Another exemplary embodiment utilizes an enzyme having a maltose binding protein amino-acid sequence fused with an N-terminus of the enzyme.

The invention discloses a leucine dehydrogenase mutant and an application thereof, belonging to the technical fields of enzyme engineering and microorganism engineering. The present invention provides a leucine dehydrogenase mutant, compared with the leucine dehydrogenase whose amino acid sequence is shown in SEQ ID NO.2, the 72nd amino acid of the leucine dehydrogenase mutant is Mutating from lysine to alanine, the present invention conducts site-directed mutation of basic amino acid residues in the substrate channel of leucine dehydrogenase for the first time, transforms the structure and environment near the possible substrate binding site of the enzyme, and obtains Leucine dehydrogenase for more efficient production of L‑2‑GABA. The leucine dehydrogenase mutant leucine dehydrogenase mutant K72A that the substrate tolerance provided by the present invention improves can tolerate 4.5g / L 2-ketobutyric acid and for the substrate 2-ketobutyric acid Catalytic activity increased by 15%.

The invention relates to the biotechnology field, specifically relates to an improvement method of natural anticancer peptide. The method comprises the design improvements at two stages by use of natural polypeptide as a template; in the design improvement at the first stage, a series of polypeptide derivatives are obtained by changing the percentage of polypeptide net charge and the hydrophobic residue in the polypeptide; in the design improvement at the second stage, the variety and the number of the screened polypeptide amino acid residue are unchanged, only the primary amino acid sequence is changed, so that the alpha-helix in the high-level structure is located at different positions or disappeared to obtain the series of polypeptide again. The anticancer peptide prepared by use of the method disclosed by the invention is not only high in anticancer property, but also small in toxicity and safer to the human body.

[Problem] To provide a polymer for nucleic acid delivery. [Solution] A polymer compound selected from a homopolymer of (a) and a block copolymer of (b). (a) A homopolymer comprising a polyglycidyl chain having a side chain including a primary amine. (b) A block copolymer of a polyglycidyl chain having a side chain including a primary amino acid, and a polyethylene glycol chain.

The invention relates to a preparation method and application of a composite targeting drug controlled release system using gold nano-cages as a carrier, and effectively solves the problems of existing tumor therapeutic drugs such as large side effects, poor therapeutic effect and tumor photothermal therapy. Add Re2O3, Fe(NO3)3, Mn(NO3)2, Zn(NO3)2, citric acid, ethylene glycol, gold nanocages to HNO3, adjust pH to 6, centrifuge, reconstitute the precipitate with water, adjust pH to 6 , dried to obtain gold nano-cages coated with manganese-zinc ferrite; heat the temperature-sensitive material, add drugs and gold nano-cages coated with manganese-zinc ferrite, and centrifuge to obtain manganese-zinc ferrite and temperature-sensitive materials gold nanocages-manganese-zinc ferrite complex; add OPSS-PEG-SVA into PBS buffer solution with primary amino target molecule, add gold nanocages-manganese-zinc ferrite complex, centrifuge, and precipitate with PBS buffer It can be washed with liquid to form a compound targeted drug controlled release system with gold nano cages as a carrier. The present invention simultaneously achieves the purposes of hyperthermia, chemical (gene) therapy, targeting and controlled release.

This invention pertains to nucleic acid fragments encoding plant glucosyltransferases, heretofore undescribed, that exhibit catalytic activity with p-hydroxybenzoic acid (pHBA) as a substrate and only attach glucose to the aromatic carboxyl group of pHBA, to form the pHBA glucose ester. These enzymes have potential applications both in vitro and in vivo, and their primary amino acid sequences can be used to identify other proteins that have similar kinetic properties.

The invention relates to a method for preparing bonito stick protein hydrolysate with an effect of reducing uric acid. The method comprises the following main steps of raw material heat treatment, restriction digestion, membrane separation-anion exchange chromatography-gel filtration chromatography separation, concentration and spray drying so as to obtain the bonito stick protein hydrolysate with an effect of reducing uric acid. The amino acid analysis indicates that the zymolyte peptide fragment primary amino acid sequence contains four amino acids, namely histidine, arginine, lysine and threonine, the total mass content of the four amino acids is 70 percent of the total amino acid content of zymolyte. MALDI-TOF-MS mass spectrum determines that the molecular weight of the main peptide effective ingredient is less than 700Da. In-vitro uric acid reduction experiments prove that the bonito stick protein hydrolysate has a remarkable effect of inhibiting generation of uric acid, and has an inhibition rate over 50 percent; an oteracil potassium molded hyperuricemic rat animal model indicates that the bonito stick protein hydrolysate can be used for remarkably reducing the level of serum uric acid and serum creatinine of rats, and shows a relatively good kidney protecting effect.